Lifecore Biomedical
LFCR
93 hedge funds and large institutions have $275M invested in Lifecore Biomedical in 2021 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 35 increasing their positions, 38 reducing their positions, and 6 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
4% less capital invested
Capital invested by funds: $288M → $275M (-$12.8M)
8% less repeat investments, than reductions
Existing positions increased: 35 | Existing positions reduced: 38
2.22% less ownership
Funds ownership: 90.79% → 88.57% (-2.2%)
3% less funds holding
Funds holding: 96 → 93 (-3)
50% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 6
66% less call options, than puts
Call options by funds: $45K | Put options by funds: $134K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CSC
Cove Street Capital
El Segundo,
California
|
+$6.29M |
| 2 |
IEFM
IQ EQ Fund Management
Dublin 2,
Ireland
|
+$1.22M |
| 3 |
Renaissance Technologies
New York
|
+$1.06M |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.06M |
| 5 |
BlackRock
New York
|
+$1.04M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nuveen
Charlotte,
North Carolina
|
-$3.51M |
| 2 |
AC
AltraVue Capital
Bellevue,
Washington
|
-$2.91M |
| 3 |
Russell Investments Group
London,
United Kingdom
|
-$2.76M |
| 4 |
Morgan Stanley
New York
|
-$1.92M |
| 5 |
HFA
Harbert Fund Advisors
Birmingham,
Alabama
|
-$1.65M |
LFCR Hedge Fund Activity: Q1 2021 in Review
93 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Lifecore Biomedical (LFCR) for Q1 2021, worth a combined $275M — down 4.5% from $288M a quarter earlier.
Sellers outnumbered buyers: 6 funds closed out of LFCR and 3 opened new positions — a net loss of 3 holders — while 38 trimmed existing stakes and 35 added.
The largest buyer was Cove Street Capital, adding an estimated $6.29M. The largest seller was Nuveen, cutting an estimated $3.51M.
- 93 institutional investors held Lifecore Biomedical (LFCR) as of Q1 2021, down from 96 in Q4 2020.
- Funds reported $275M of Lifecore Biomedical stock for Q1 2021, down 4.5% quarter-over-quarter.
- 3 funds opened new Lifecore Biomedical positions in Q1 2021 and 6 closed out, a net change of -3 holders.
- The largest Lifecore Biomedical buyer in Q1 2021 was Cove Street Capital, an estimated $6.29M added.
- The largest Lifecore Biomedical seller in Q1 2021 was Nuveen, an estimated $3.51M sold.
Based on aggregated 13F filings for Q1 2021.